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4. Introduction 
4.1 Pain pathways 
A consequence of a surgical procedure is tissue damage and direct mechanical nerve 
stimulation. Tissue damage leads to the release of inflammatory mediators such as histamine, 
substance P, bradykinin and prostaglandins with systemic effects on the central nervous 
system (CNS) and pain modulation. The inflammatory mediators also activate the peripheral 
nociceptors locally, and the nociceptive signals are transmitted to the CNS through the Aβ, 
Aδ and C nerve fibres. Aβ fibres have a large diameter and are highly myelinated. They have 
a low activation threshold, and are therefore responsible for tactile information. Aδ fibres 
have a higher activation threshold. Their myelin sheath is thinner than in Aβ fibres, and their 
conduction speed is therefore slower. C fibres are unmyelinated, and the slowest conductive 
nerve fibres. They have a high activation threshold, and therefore need strong stimuli to be 
activated. Such stimuli are often harmful as they may result in tissue damage. Aδ and C fibres 
respond to noxious stimuli like mechanical, thermal or chemical stimuli.1 The noxious signals 
from peripheral somatic and visceral sites end in the dorsal horn of the spinal cord (fig. 1). 
In the dorsal horn, there is an integration of peripheral nerve transmission and descending 
pain modulatory signals.  
The noxious signals from the dorsal horn are then transmitted on the contralateral part of the 
medulla through the spinothalamic, the spinoreticularis and spinomesencephalic tracts to the 
brainstem. The noxious signals are further transmitted through the thalamus, and the signals 
finally end in the cortex and result in a conscious perception of pain. In the brainstem there 
are collateral branches to the periaquaductal gray matter (PAG) where a regulation of 
nociception takes place. From the periaquaductal gray matter there are branches to the 
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nucleus raphe magnus (NRM), which again has a controlling function on neurons in the 
medulla through descending pathways. 
 
 
 
Fig. 1  
Noxious stimuli are transduced into electrical activity at the peripheral terminals of Aβ, 
Aδ and C nerve fibres. This activity is conducted to the dorsal horn of the spinal cord 
through the dorsal root ganglion. The noxious signals are then transmitted on the 
contralateral part of the medulla through the spinothalamic, the spinoreticularis and 
spinomesencephalic tracts to the brainstem. The noxious signals are further transmitted 
through the thalamus, and to the cortex, where the sensation of pain is experienced. 
With permission from Medscape®. 
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A continuous feedback mechanism regulates the nociceptive activity between the connections 
in the brainstem and the medulla. In the brainstem there are also connections to the centres 
which regulate the blood pressure, heart rate and respiration. These connections form the 
basis for the immediate increase in blood pressure, heart rate and respiration rate in the case 
of acute noxious stimulation.  
4.2 Postoperative pain and analgesia 
Pain after surgery has a major effect on patient recovery, and may have implications on 
patient safety, the perceived patient care quality as well as health care economics. The most 
common complications of ineffective pain control include immobilization, poor wound 
healing, chronic pain, deep vein thrombosis, pneumonia, coronary ischemia and insomnia.2-4 
Persistent pain in patients after surgery is reported to be between 10-50%, and major chronic 
pain is reported in about 2-10% of these patients.4 
Postoperative pain is one of the most common concerns and fears among surgical patients.5 
Even though there has been a focus on postoperative pain the last decades, a national survey 
in the United States demonstrated that 86% of the patients reported moderate, severe or 
extreme pain after surgery.5  
Pain and pain complications have both medical and financial implications; the patients have 
to stay longer in the hospital, and for some readmission to hospital is necessary, which may 
lead to dissatisfaction with the medical care.6                  
There may be a lot of reasons for why postoperative analgesia still is suboptimal in many 
patients: poor understanding of pain physiology, lack of efficient analgesics or other 
preventive and therapeutic measures as well as suboptimal application of present knowledge 
into the individual patient. Poor application of present knowledge and treatment options may 
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be a result of insufficient training of healthcare personnel and patients, fear of serious adverse 
effects and economic restrictions on drug and personnel expenses. 
The development of hyperalgesia during a surgical procedure has recently attained much 
interest in the field of pain physiology; what causes hyperalgesia and may it be prevented? 
Early multimodal analgesia also seems to be beneficial for enhanced quality of recovery.7 
Paracetamol, nonsteroidal anti-inflammatory drugs, local anaesthesia and opioids play an 
important role in multimodal analgesia.7 Opioids are still useful in general anaesthetic 
techniques and as treatment of severe postoperative pain, but their role in the development of 
hyperalgesia as well as their bothersome adverse effects makes the use of them controversial. 
Our focus has been to look into different aspects of basic pain physiology, i.e. opioid-induced 
hyperalgesia (OIH) and possibilities to prevent OIH, as well as optimal use of some present 
analgesic drugs, i.e. opioids and cyclooxygenase inhibitors.  
4.3 Nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids 
Nonsteroidal anti-inflammatory drugs (NSAIDs) 
NSAIDs are widely used in postoperative pain management, and their analgesic efficacy is 
well documented.8-10  
NSAIDs have demonstrated opioid-sparing effects after surgery,11-13 and have also an 
additive effect when administered in combination with paracetamol.14;15  
The opioid-sparing effects of NSAIDs has been demonstrated in a systematic review of 
COX-2 inhibitors.16 On average, the opioid consumption in this review was significantly 
reduced by 35%, but a significant reduction in opioid-related adverse effects was not shown. 
The authors of this review describe the reporting quality with respect to opioid-related 
adverse effects as poor. This is interesting, because in a clinical setting the points of interest 
are the adverse effects leading to torments for the patients, longer stay in the recovery unit 
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etc., not the total amount of opioids used per se. In a systematic review Marret E et al. 
demonstrated that NSAIDs significantly decreased postoperative nausea, vomiting and 
sedation.17 In this review, the morphine consumption was positively correlated with the 
incidence of nausea and vomiting. 
Therefore, it is important that clinical trials do not only register opioid consumption and 
analgesic effect, but also opioid-related adverse effects.  
The primary analgesic mechanism of NSAIDs is through inhibition of the cyclooxygenase 
(COX) enzyme. Cyclooxygenase facilitates the production of prostaglandins, which are 
important mediators of inflammation and pain (fig. 2).  
Two cyclooxygenase enzymes have been discovered; COX-1 and COX-2.18 COX-1 
facilitates the platelet aggregation19 and gastric mucosal protection,20 and COX-2 is an 
important mediator of inflammation, pain and fever.21;22 
This has resulted in the development of selective COX-2 inhibitors. The advantage of COX-2 
inhibitors is the possibility to avoid the tendency for bleeding, which may be very important 
in some types of surgery. In addition, gastrointestinal wounds and bleedings are less frequent 
with the use of COX-2 inhibitors compared to non-selective NSAIDs.23-26 A selective COX-2 
inhibition results in a more specific action on inflammation and pain. Numerous studies have 
confirmed that selective COX-2 inhibitors and non-selective NSAIDs have similar analgesic 
efficacy.27-30   
Traditionally, NSAIDs are considered to be peripherally acting drugs, but evidence has also 
clearly demonstrated analgesic efficacy through spinal COX-inhibition.31;32  
However, the concept of COX-2 as the major factor in NSAID-induced analgesia has been 
challenged. In rats, experimental studies on incisional pain have demonstrated activation of 
COX-1 in the spinal cord, and less pain behaviour after intrathecal injection of ketorolac 
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compared to a selective COX-2 inhibitor,33;34 whereas basically spinally COX-2 was 
activated in an inflammatory pain model.35 
 
 
Fig. 2 
The differential activation of two major COX enzymes involved in arachidonic 
metabolism. Arachidonic acid is liberated from membrane phospholipids by 
phospholipase A2 in response to inflammatory stimuli, and then converted to PGG2 and 
PGH2 successively be prostaglandin G/H synthases, which are termed as 
cyclooxygenases and exist in two major isoforms, cyclooxygenase-1 and 2. PGH2 is 
further converted by tissue-specific isomerases to several different prostanoids. 
With permission, Lee Y et al.: Curr Pharm Design 2005; 11:1737-55. 
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This may indicate that COX activation is different in different pain models. The analgesic 
efficacy of various cyclooxygenase inhibitors seems to be more complex than previously 
thought, and hopefully further investigations can result in a more detailed clarification of the 
analgesic mechanisms of cyclooxygenase inhibitors. 
In this thesis two NSAIDs with different selectivity in inhibiting the COX-1 and COX-2 
enzymes were compared to investigate the possibility of improving postoperative pain in a 
day-surgery unit (paper II). COX-2 inhibitors are presumed to have similar efficacy as 
traditional NSAIDs, but whether timing of nonsteroidal anti-inflammatory drugs is of 
importance in improving postoperative pain is still a question that needs to be answered. In 
paper II, the NSAIDs were administered ahead of surgery to ensure maximum effect before 
incision (preemptive analgesia). Preemptive analgesia remains controversial in managing 
postoperative pain. In a meta-analysis Ong et al.36 demonstrated that preemptive NSAIDs 
reduce analgesic consumption and delay the time to the first rescue analgesic request 
postoperatively. There was no improvement in postoperative pain scores. Another review did 
not find any significant evidence of better postoperative pain relief by administering NSAIDs 
as preemptive medication.37  
As described above, experimental studies in rats after incisional pain have demonstrated 
activation of COX-1 in the spinal cord, and less pain behaviour after intrathecal injection of 
ketorolac before incision compared to a selective COX-2 inhibitor. Therefore, it would be 
interesting to investigate, in a clinical setting, if there are any differences between a COX-1 
inhibitor and a COX-2 inhibitor administered as preemptive medication with respect to 
postoperative pain and analgesic consumption. 
Opioids 
The opium poppy is known from Mesopotamia since 3-4000 years ago. All antique 
civilizations have descriptions of the use of the opium poppy, especially as a tranquillizer and 
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sleep-inducing drug. The name opium has its origin in the Greek word opos meaning juice. In 
1806, a pure substance was isolated from the opium poppy and named after the Greek God of 
dreams: Morpheus. 
Opioids are a generic term for all compounds with the ability to bind the opioid receptors. 
Opiats are natural opium alkaloids isolated from the opium poppy, like morphine and 
codeine. 
Opioids can be classified in several ways:  
1)  By the way they are produced:  
     - Naturally occurring: Morphine and codeine. 
     - Semisynthetic: Heroin, oxycodone and buprenorphine. 
     - Synthetic: Alfentanil, fentanyl, ketobemidone, methadone, pethidine, remifentanil and 
     sufentanil.     
2)  By the type of receptor action: 
     - Agonists: Alfentanil, codeine, fentanyl, ketobemidone, methadone, morphine, 
      oxycodone, pethidine, remifentanil and sufentanil.     
     - Mixed agonists/antagonists: Buprenorphine and nalbuphine. 
     - Antagonists: Naloxone and metylnaltrexone. 
3)  By their origin:  
      - Endogenous opioids: Enkephalin, endorphin and dynorphin. 
      - Exogenous: Opioid drugs. 
There are several different opioid receptors: μ (my), δ (delta), κ (kappa) and ORL1 
(nociceptin/orphanin FQ). 
The most common opioids are selective µ-opioid receptor agonists: alfentanil, codeine, 
fentanyl, ketobemidone, methadone, morphine, remifentanil and oxycodone. Opioid receptors 
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are widely distributed throughout the CNS; e.g. in the substantia gelatinosa, the 
periaquaductal gray matter (PAG), the thalamus, the amygdala and the cortex (fig. 3). 
 
 
 
Fig. 3 
Group average (fixed effect) activation maps and time courses of signals (±1 SEM, gray 
area) in response to intravenous remifentanil boluses. The time courses show the 
average signal changes over the three repetitions of remifentanil administration and 
voxels within the region of interest in six subjects. The intravenous injection of the drug 
occurred at 0 s. 
With permission, Leppä et al.: Neuroimage 2006;31:661-9. 
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There are also opioid receptors in the gut38;39 and in inflammatory tissue.40 
The CNS is the main target for opioids. Opioids inhibit the ascending transmission of noxious 
stimuli in the dorsal horn. Opioids can also activate the pain inhibitory system by inhibiting 
the activity of GABAergic neurons. This is mediated in the PAG through descending 
pathways in the rostral ventral medulla, and inhibits nociceptive responses in the spinal dorsal 
horn. 
Opioids have a large number of adverse effects like nausea, vomiting, itching, dizziness, 
sedation, hallucinations, urinary retention, sleep disturbances, respiratory depression etc. It is 
therefore important that the patients are not “overloaded” with opioids. An enhanced use of 
opioids increases the risk of adverse effects. 
Different opioids have different pharmacological properties, and choosing the right opioid for 
the specific surgical procedure may be of importance to achieve better postoperative 
analgesia and less adverse effects.  
Two common used opioids are morphine and oxycodone. 
Morphine is the “gold standard” among the opioids. It is a classical µ-receptor agonist, and 
the most commonly used opioid worldwide. Morphine has an active metabolite, M-6-G, 
which accumulates in the patients suffering from renal failure, and in these patients care 
should be taken to avoid an overdose of morphine. Morphine has low lipid solubility 
compared to many other opioids, and is therefore slow-acting because the blood-brain barrier 
transport is slow. 
Oxycodone is an old opioid with a growing clinical use the last years. The pharmacological 
effects of oxycodone have been supposed to be typical of a µ-opioid, closely resembling 
morphine.41 Traditionally, it has been presumed a 1:1 ratio in analgesic potency between 
morphine and oxycodone intravenously and intramusculary in postoperative pain.42;43 These 
studies have been performed on various types of surgery, with both somatic and visceral pain. 
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However, one study on patients undergoing abdominal surgery demonstrated a 2:3 ratio in 
analgesic potency between oxycodone and morphine intravenously. In addition, the patients 
who received oxycodone were less sedated.44 This may suggest a potential better analgesic 
efficacy of oxycodone in visceral pain with less adverse effects. In a multi-modal, tissue-
differentiated experimental pain model in humans, equipotent doses of oxycodone and 
morphine demonstrated that oxycodone had a better analgesic effect in visceral pain.45;46 Ev 
Even though these studies may indicate that oxycodone is more efficient in the treatment of 
visceral pain compared to morphine, this question is still unsettled.hTheref 
In paper III, these two opioids were compared with respect to postoperative pain and adverse 
effects. The approach in this study was to investigate whether one of those opioids was more 
efficient in the treatment of postoperative pain presumed to be dominated by visceral pain 
stimulation.  
The pharmacological characteristics and differences between oxycodone and morphine are 
listed in table 1.  
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Table 1 
 Oxycodone Morphine 
Chemical structure 
  
Receptor binding profile µ-receptor agonist47;48 µ-receptor agonist 
Receptor affinity (to µ-receptor) > 20 times less than morphine49  Higher affinity to the µ-receptor than oxycodone49 
Receptor activation 3-8 times higher concentration is needed to 
activate the G-protein compared to morphine 
([35S]GTPγ assay)49-51 
Lower concentration to activate the G-protein 
than oxycodone49-51 
Analgesic efficacy in 
postoperative pain                
Intravenous: Between 1:1 and 1:1.542-44;52 
Epidural: Less potent compared to morphine 
(8.4-9.8:1)53                                                  
Oral: Controlled-release (CR) oxycodone 1.8 
times more potent than CR morphine in total 
effect54 
Intravenous: Between 1:1 and 1.5:142-44;52                 
Epidural: More potent compared to oxycodone53      
Oral: Less potent than oxycodone54 
 
Adverse effects Classical µ-opioid-related adverse effects, but 
less hallucinations55-57 and itching55 (less 
histamine release) than morphine 
Classical µ-opioid-related adverse effects. More 
hallucinations and itching than oxycodone55-57 
Metabolites O-demethylation in the liver to oxymorphone 
(no analgesic efficacy)58 and N-demethylation 
to noroxycodone (no analgesic efficacy)50  
Metabolized in the liver to                      
M-6-G (analgesic efficacy), M-3-G (no analgesic 
efficacy) and normorphine (analgesic efficacy).59    
Volume of distribution 2-3 L/kg60 1-4 L/kg59;61 
Elimination Excreted in urine. Oxycodone and 
noroxycodone as unconjugated, and 
oxymorphone as conjugated62 
Excreted mainly through urine59 
Peak plasma concentration 
following i.v. administration 
Within 25 min41;60 Within 20-30 min63;64 
T ½ following intravenous 
administration 
Approximately 2-3 hours60 Approximately 2-3 hours61;65 
Protein binding (in vitro) Approximately 38%66 Approximately 31%66 
Lipid solubility Similar to morphine66 Low lipid solubility compared to most others 
opioids (e.g. fentanyl)66 
Blood-Brain Barrier transport Active influx of oxycodone into the CNS?67;68 None known active influx  
Oral bioavailability Approximately 60%62 18-24%69;70 
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4.4 Opioid-induced hyperalgesia (OIH) 
There is growing evidence that opioids, in addition to alleviate pain, can facilitate pain.71 This 
phenomenon is called opioid-induced hyperalgesia (OIH). Hyperalgesia is defined as 
hypersensitivity to nociceptive stimuli, and this is due to the activation of pro-nociceptive 
mechanisms (sensitization of pro-nociceptive pathways). It is sometimes difficult to 
differentiate between hyperalgesia and tolerance. Hyperalgesia is a leftward shift of the 
stimulus-pain curve (fig. 4 A). The result is that a non-painful stimulus may become noxious 
(allodynia), or that a normally painful stimulus increases in intensity. Tolerance is a loss of 
analgesic opioid efficacy over time due to the use of opioids. As a consequence, larger doses 
of opioids are necessary to achieve the same efficacy (desensitization of anti-nociceptive 
pathways). Tolerance is a rightward shift of the opioid dose-effect curve (fig. 4 B), where the 
opioid looses its potency. 
Fig. 4  
                                                                                                  
A) Hyperalgesia is a leftward shift of the 
stimulus-pain curve, e.g. a non-painful 
stimulus becoming noxious (allodynia) or 
that a normally painful stimulus increases 
in intensity. 
 
 
 
 
 
 
 
 
 
B) Tolerance is a rightward shift of the 
dose-effect curve, where the drug looses its 
potency.  
 
With permission, Koppert W: Acute Pain 
2007; 9:21-34. 
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Opioid-induced hyperalgesia is explained as when patients receiving opioids become more 
sensitive to pain as a consequence of the opioid therapy itself. The evidence of OIH and the 
possibility to prevent OIH can be divided into four types of studies:  
1. Studies on former opioid addicts 
2. Animal experimental studies 
3. Human experimental studies 
4. Studies on surgery patients 
 
1. Studies on former opioid addicts 
Several studies on current and former opioid addicts have been carried out.72-75  
Three of these studies have compared either former addicts on methadone to former addicts 
free of methadone,72 or former addicts on methadone to a control group (healthy 
volunteers).73;75 
The subjects were tested for electrical pain and cold pressor pain. The subjects on methadone 
detected pain significantly earlier and had significantly lower pain tolerance than the control 
group or former addicts free of opioids.73;75  
From this, one may conclude that current opioid addicts are hyperalgesic, and that the 
condition is reversible with the withdrawal of the opioid therapy (methadone). 
2. Animal experimental studies 
Several studies with different models in rats have clearly demonstrated that opioids like 
heroin, morphine and fentanyl induced hyperalgesia, and that activation of the NMDA 
receptor in the medulla seems to play a key role in the development of opioid-induced 
hyperalgesia.76-84 
In these studies, treatment with NMDA receptor antagonists like ketamine and MK-
801(dizocilpine maleate) prevented the development of hyperalgesia. It has also been 
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demonstrated that opioids, like remifentanil, activates the NMDA receptor in the dorsal horn 
neurons.85 
Prostaglandins, like PGE2, can stimulate glutamate release from astrocytes and from the 
spinal cord dorsal horns with subsequent activation of the NMDA receptors.86;87 
Subsequently, cyclooxygenase inhibitors were found to antagonize this NMDA receptor 
activation.88;89 Therefore, it is not surprising that COX-2 inhibition attenuated the level of 
thermal hyperalgesia induced by paw carrageenan injection.35  
In rats, OIH induced by subcutaneous fentanyl was prevented by administration of 
intraperitoneal or intrathecal gabapentin.90 Gabapentin has a binding site to the alpha-2-
subunit of the calcium channel,91 and the antinociceptive efficacy of gabapentin seems to 
depend on the affinity to this receptor site.92 The mechanism by which gabapentin prevents 
OIH is not totally understood. The underlying hypothesis is that gabapentin inhibits the 
glutamate release by binding to the alpha-2-delta subunit of spinal voltage-gated calcium 
channels. As opioids increase the level of presynaptic glutamate, this may explain way 
gabapentin has the ability to reduce OIH. 
In rats, magnesium also seems to prevent OIH after fentanyl administration.93 The main 
mechanism seems to be through a voltage-gated antagonist action at the NMDA receptor, and 
magnesium is therefore considered as a NMDA receptor antagonist.94 
Nitrous oxide (N2O) is a NMDA antagonist,95 and in rats treated with N2O, fentanyl-induced 
hyperalgesia in inflammatory and incisional pain models was reduced.96 Sevoflurane also 
seems to have a weak anti-hyperalgesic effect.97  
3. Human experimental studies 
Different experimental pain models have been performed in human volunteers.  
a) Short-term infusion of remifentanil with electrical pain. To provoke pain and secondary 
hyperalgesia, two microdialysis fibres equipped with internal stainless steel wires are inserted 
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intradermally in the central volar forearm, and a constant current stimulator then provokes 
pain. This model has been proven to create a stable area of secondary hyperalgesia to 
punctate stimuli by an activation of primarily mechanoinsensitive “silent” C-nociceptors.98 
In this model, remifentanil induced postinfusion hyperalgesia,99;100 and different drugs have 
been tested to investigate the possibility to prevent/diminish this postinfusion hyperalgesia. 
Drugs like ketamine99;101 and parecoxib102 have reduced the area of secondary hyperalgesia to 
punctate stimuli.  
b) Short-term infusion of remifentanil with heat-capsaicin model. Sensitization is induced by 
heating the forearm skin with a thermode at 45 °C. Capsaicin cream applied on the skin 
induces pain and primary and secondary hyperalgesia. The area of secondary hyperalgesia 
and allodynia can then be measured before, during and after remifentanil infusion. This 
model demonstrated that during remifentanil infusion, the area of secondary hyperalgesia was 
reduced,103 and after withdrawal, the areas of secondary hyperalgesia and allodynia were 
enlarged.104 
c) Short-term infusion of remifentanil with electrical pain (applied on the anterior tibial 
muscle) and pressure pain test. In this study, remifentanil induced hyperalgesia and tolerance 
only in the pressure pain test and was not suppressed by ketamine.105 
d) Morphine has demonstrated hyperalgesia in the cold pressor test.106 
 Summary of the results from experimental pain models on OIH in humans:  
Both the electrical model, the cold pressor model, the heat model and the mechanical 
(pressure) model demonstrate remifentanil-induced hyperalgesia. OIH in humans can be 
prevented by administration of ketamine, a NMDA receptor antagonist. COX-2 inhibition 
also seems to have the possibility to prevent OIH. The mechanism behind this is probably 
through the NMDA receptor; prostaglandins, like PGE2, can stimulate glutamate release from 
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astrocytes and from the spinal cord dorsal horns with subsequent activation of the NMDA 
receptors.86;87 Subsequently, cyclooxygenase inhibitors can antagonize this NMDA receptor 
activation.88;89 
4. Studies on surgery patients 
In clinical trials, it is difficult to demonstrate OIH directly. This is due to the lack of good 
models to differentiate between OIH and acute tolerance. The studies that have been 
performed demonstrate a more indirect evidence of OIH. In surgery patients, several studies 
have been performed comparing a “low dose” opioid group vs. a “high dose” opioid group. 
Three of these studies demonstrated higher opioid consumption and higher pain scores 
postoperatively in the “high dose” group.107-109 One study did not demonstrate increased 
postoperative opioid consumption or pain scores in the group receiving remifentanil, when 
compared to a group receiving sevoflurane.110 An important objection to this study is that 
both groups received 50% nitrous oxide in oxygen. Nitrous oxide is a NMDA antagonist,95 
and may therefore have protected the remifentanil group from developing OIH. 
These four studies did not differentiate between OIH and acute tolerance, as both the amount 
of postoperative opioid consumption and pain scores was used as main result parameters. To 
address this problem another clinical trial has tried to estimate the area of hyperalgesia and 
allodynia around the wound postoperatively. The investigators demonstrated that the “high 
dose” opioid group had a significantly larger area of pinprick hyperalgesia and allodynia near 
the wound compared to the “low dose” opioid group.111 In this study, there was also a third 
group receiving a sub-analgesic infusion of ketamine in addition to “high dose” opioid. 
Ketamine prevented peri-incisional allodynia and hyperalgesia, and enhanced the opioid 
consumption postoperatively. 
One study has demonstrated that lornoxicam, a non-selective NSAID, significantly 
diminished the acute opioid tolerance and/or hyperalgesia caused by fentanyl.112 
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Interestingly, this study suggests that administration of only three boluses of fentanyl 3 µg/kg 
i.v. during approximately 45 min leads to enhanced postoperative opioid consumption 
compared to placebo (0.9% NaCl).  
The mechanisms of OIH:  
It seems that OIH can be induced by peripheral, spinal and systemic administration of 
opioids.71 Most of the studies on OIH have been done with µ-opioid receptor agonists. The 
dorsal horn of the medulla plays a crucial role in the development of OIH (fig. 5). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5  
1. Sensitization of peripheral nerve endings.  
2. Enhanced descending facilitation of nociceptive signal transmission.  
3. Enhanced production and release as well as diminished reuptake of nociceptive 
neurotransmitters. 
4. Sensitization of second-order neurons to nociceptive neurotransmitters. 
The figure does not illustrate all the potential mechanisms underlying opioid-induced 
hyperalgesia, but rather depicts those that have been more commonly studied.  
DRG = Dorsal Root Ganglion; RVM = Rostral Ventral Medulla. 
With permission, Angst MS, Clark JD: Anesthesiology 2006; 104:570-87. 
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Fig. 6  
Schematic illustration of the pronociceptive mechanisms mediated by μ-agonists. The 
increase of cyclic adenosine monophosphate (cAMP) causes a heightened release of 
excitatory amino acids. In addition to the increase on cAMP, the activation of protein 
kinase C (PKC) plays a major role in the postsynaptic processes. The phosphorylation 
of the NMDA receptors causes an increase of intracellular calcium (Ca2+) with a 
heightened production of nitric oxide (NO).  
With permission, Koppert W, Schmelz M: Best Pract Res Clin Anaesthesiol 2007; 
21:65-83.  
 
The NMDA receptor seems to play the most important role in the development of OIH 
(fig. 6). Opioids bind the NMDA receptor (postsynaptic), and this leads to the generation of 
NO. Nitric oxide then diffuses out of the postsynaptic neuron enhancing presynaptic release 
of glutamate. Glutamate then activates the NMDA receptor, and the NMDA receptor is 
amplifying the afferent pain input, leading to hyperalgesia. 
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Based on current knowledge, how do we deal with OIH in surgery patients today?  
In a practical, clinical setting it is difficult to differentiate between OIH and acute tolerance in 
surgery patients. Still, it is important for the clinician to know that with the administering of 
large doses of opioids the patient is likely to experience more pain and needs more opioids 
postoperatively, which is not a desirable situation. If the planned surgical procedure is very 
painful or will last for several hours, there is an increased likelihood that large doses of 
opioids will be used, and strategies to reduce opioid dosing are necessary. 
Strategies to reduce peroperative opioid consumption: 
a) If possible, inhalation gases should be used. 
Inhalation gases has an analgesic effect,113 and by using inhalation anaesthetics, the opioid 
consumption may be reduced. 
b) Use of local and regional anaesthesia.  
Use of local anaesthetics infiltration or regional blocks may reduce peroperative opioid 
consumption,114 and thereby reducing the risk of postoperative OIH. 
Preincisional intervention with epidural reduced postoperative opioid consumption and 
hyperalgesia definited by the von Frey pain threshold near the wound.115 A more aggressive 
use of epidural anaesthesia during surgery seems therefore to be preferable. The systemic use 
of intraoperative opioids can be reduced by using epidural anaesthesia actively as an 
important analgesic component during surgery.  
c) Use of N2O and sevoflurane. 
Nitrous oxide is a NMDA receptor antagonist,95 and has demonstrated reduced hyperalgesia 
in opioid-exposed rats.96;116 There is also evidence that sevoflurane has antihyperalgesic 
effect.97 As far as we know, no clinical study on surgery patients investigating N2O with 
respect to OIH has been performed. 
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d) Use of ketamine.  
Ketamine is the most potent NMDA receptor antagonist in clinical use. Joly et al.111 
administered ketamine 0.5 mg/kg as a bolus, followed by an 5 µg/kg/min infusion during 
surgery and 2 μg/kg/min until 48 h after the end of surgery in a group receiving “high dose” 
remifentanil. This regimen prevented increased postoperative morphine consumption. 
On the other hand, intraoperative infusion of low dose ketamine infusion alone did not 
prevent remifentanil-induced acute tolerance and/or hyperalgesia.117;118 
More studies are needed before it is possible to put forth a recommendation of a practical use 
of ketamine to prevent OIH in surgery patients. 
e) Use of NSAIDs. 
In an experimental pain model in humans, NSAIDs seem to prevent OIH.102 One clinical 
study indicates that NSAIDs may also have this potential in surgery patients.112 
f) Use of magnesium. 
Magnesium is a NMDA receptor antagonist, and seems to prevent OIH after fentanyl 
administration in rats.93 One clinical study has also demonstrated less postoperative morphine 
consumption with infusion of magnesium,119 but this study was not designed to investigate 
opioid-induced hyperalgesia and/or tolerance. 
g) Opioid rotation 
Opioid rotation has been suggested as a treatment to avoid/reduce OIH.71 There are several 
reports of cancer patients with escalating opioid doses and pain supposed to be hyperalgesia, 
who has profited when changing from one opioid to another.120 Changing from phenantren to 
peperidin derivatives has been suggested as a treatment to reduce OIH.71  
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Conclusion:  
The strongest and most consistent evidences of OIH are derived from studies on normal 
volunteers and experimental studies in rats exposed to opioids. There is limited evidence for 
the development of OIH in surgery patients,121 however several clinical trials indirectly 
indicate that OIH might be a relevant problem in surgery patients.107-109;111;112 
In this thesis we have tried to investigate the possibility of reducing postoperative pain and 
analgesic consumption by pretreating surgery patients with fentanyl before remifentanil-
based anaesthesia. This is a kind of opioid rotation or shifting of opioids to avoid possible 
postoperative opioid-induced hyperalgesia (paper I).  
COX-2 inhibitors also seem to prevent/reduce OIH.102 In paper IV, two different 
experimental pain models were used to investigate OIH in humans. COX-1 and COX-2 
preferring inhibitors were used as pretreatment to investigate any differences in preventing 
OIH between COX-1 and COX-2 inhibition. 
4.5 Measurement of pain in clinical trials 
When measuring pain in clinical trials, it is important that the trauma is similar in all patients. 
This is achieved by only including patients scheduled for the same surgical procedure and 
involving as few surgeons as possible. 
As several factors are involved in the perception of pain, the measurement of pain is 
complex. Physiological factors,122 psychological factors,123;124 etnicity,125 gender,126 age127 
and earlier experience with pain128 are some of the factors having an impact on postoperative 
pain. In RCTs, confounding factors like these must be eliminated as far as possible.  
Cultural factors and traditions for pain behaviour are also factors with impact on pain.125 In 
Norway, the population is quite conformable compared to many other countries, e.g. the 
United States. We included patients with a good understanding of the Norwegian language. 
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This means that the patients in our studies are mostly Caucasians with the same cultural 
background.  
Gender has an impact on postoperative pain, as women are known to experience more 
postoperative pain compared to men.126 When both women and men are included in the same 
RCT, it is important that the gender distribution is similar in the comparing groups. 
Age also has an impact on postoperative pain; the postoperative opioid consumption 
decreases with increased age.127  
Patients with chronic pain and/or regular use of pain medication should not be included in 
basic clinical pain trials. These patients often have more postoperative pain and need more 
opioids to achieve pain relief. If these patients are included and are imbalanced in parallel 
groups, the results may be unpredictable. 
To avoid many of the known confounding factors with respect to postoperative pain, the ideal 
setting in a clinical trial is the same, standardized procedure with only one gender. In 
addition, the age distribution should not be too wide. Reduced number of confounders may 
increase the statistical power and sensitivity in pain studies, but the conclusions may be less 
valid when extrapolated to groups of patients not being included in the study. 
In the three clinical trials (paper I-III), the patients were well medicated with analgesic (local 
anaesthetics, NSAIDs and paracetamol) and antiemetics (droperidol, ondansetron and 
propofol anaesthesia). Of course, good basic pain prophylaxis makes it more difficult to 
actually find any differences in pain and adverse effects like nausea and vomiting between 
the groups. It is possible that actual differences are not discovered. On the other hand, if 
differences are found, this may give a stronger indication of actual differences between the 
comparing groups. It may be argued that differences which only appear in a comparison with 
inferior pain regimens in placebo groups are not as relevant in clinical practice. In clinical 
practice we have to look for improvements when new modalities are administered on the top 
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of present pain regimens. The use of placebo group has also an ethical aspect. Some patients 
may receive a less efficient pain treatment, and this could be a problem when applying for 
approval from the ethical committee. This is especially true if the analgesic efficacy has been 
demonstrated in previous placebo controlled studies, and when the goal of the new study is to 
put this into a clinical context. 
In the clinical studies we chose to mimic the pain treatment that are actually used in our 
hospital. This makes it easier to extrapolate the results to a real clinical situation. 
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5. Aims of the thesis 
The overall aim of the thesis was to investigate clinical and experimental aspects of 
improving postoperative analgesia by testing different analgesic drugs and by looking for 
means of modulation of postoperative opioid-induced hyperalgesia.  
In paper II and paper III, two NSAIDs and two opioids, respectively, were compared to 
investigate the possibility of improving postoperative pain control.  
In paper I and paper IV, the aim was to investigate opioid-induced hyperalgesia, and the 
possibility to reduce or prevent postoperative pain or hyperalgesia by pretreating the patients 
with opioid (fentanyl) or NSAIDs before remifentanil infusion. 
The following hypotheses were tested: 
In paper II, etoricoxib (a predominantly COX-2 inhibitor) vs. ketorolac (a predominantly 
COX-1 inhibitor) was compared. The primary hypothesis was that etoricoxib would provide 
similar maximum early postoperative analgesia as ketorolac. The secondary hypothesis was 
that etoricoxib would provide a better analgesic effect after discharge from the hospital.  
In paper III, comparison of the analgesic potency, pain scores and adverse effects of 
intravenous oxycodone vs. morphine was done in a clinical model of postoperative visceral 
pain. The main hypothesis was that oxycodone and morphine were equipotent as analgesics, 
in terms of doses measured in mg and with similar efficacy/adverse effect profile. 
In paper I, the hypothesis was that pretreatment with fentanyl prior to induction of 
remifentanil-based anaesthesia would decrease the self-rated pain scores and opioid 
consumption in the postoperative period. 
In paper IV, two different experimental human pain models were used to investigate the 
possibility of demonstrating remifentanil-induced postinfusion hyperalgesia; a model using 
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electrically evoked pain and a cold pressor test. At the same time, the subjects were 
pretreated with parecoxib or ketorolac to investigate the possibility of preventing opioid-
induced hyperalgesia with different types of COX-inhibitors. The main hypothesis was that 
remifentanil would induce postinfusion hyperalgesia in both experimental models. The 
secondary hypothesis was that parecoxib and ketorolac would prevent or diminish this 
postinfusion hyperalgesia in a similar way in both experimental models. By comparing 
parecoxib (a predominantly COX-2 inhibitor) against ketorolac (a predominantly COX-1 
inhibitor), we had the opportunity to investigate if there were any differences in preventing 
remifentanil-induced hyperalgesia by inhibiting either the COX-1 or the COX-2 enzyme. 
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6. Materials and methods 
6.1 Study design, approval and registration 
The study design in all four studies was prospective, randomized and double-blind.  
In the clinical trials (paper I-III), two groups were compared.  
The last trial was also placebo-controlled with a crossover design including healthy 
volunteers (paper IV). In this trial, each subject went through four sessions: control, 
remifentanil, parecoxib + remifentanil and ketorolac + remifentanil. Only males were 
included because the pain threshold level is fluctuating in women depending on where in the 
menstrual cycle they are. As four sessions were performed, the pain threshold in women may 
vary from one session to another, and this is a confounding factor. 
In all four papers the randomization was based on computer-generated codes stored in 
sequentially numbered, sealed envelopes. A person, who did not participate in the handling or 
the assessment of the patients/volunteers, was responsible for preparing these envelopes, and 
for opening the envelopes and preparing the medication. The appearance of the syringes (or 
tablets) was the same, and the investigator (and the patient/volunteer) was therefore blinded. 
Before start, the studies were approved by the Regional Committee for Medical Research 
Ethics in South-Eastern Norway and by the local health institution’s privacy protection 
representative. The last trial (paper IV) was also approved by the Norwegian Medicines 
Agency before start, as the study involved the use of drugs in volunteers and not for an 
approved clinical indication with approved doses.  
All trials have been registered in ClinicalTrials.gov. ClinicalTrials.gov is a service of the U.S. 
National Institutes of Health. It is a registry of clinical trials conducted around the world, and 
it is currently compulsory to register clinical trials before start. If not, the possibility to 
publish the results is limited.129;130  
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6.2 Patients and volunteers 
In the clinical trials (paper I-III), adult persons (18-70 yr) were recruited after a written 
informed consent had been obtained. The exclusion criteria were regular use of paracetamol, 
NSAIDs, corticosteroids, antiemetics or opioids. Contraindications for 
NSAIDs, obesity (paper I) and pregnancy (paper II) were also exclusion criteria. All the 
patients were ASA physical status I–II. 
In paper IV, volunteers were recruited after a written informed consent had been obtained. 
Most of these volunteers were healthy male students, with no known drug allergy or no use of 
medication during the experiment. Alcohol or drug abuse was also exclusion criteria. 
6.3 Surgery and anaesthesia in paper I-III 
In paper I, all patients underwent ACL repair. Both men and women were included.  
In paper II, women scheduled for ambulatory, laparoscopic gynaecological surgery were 
included. All kinds of minor to moderate day surgical procedures were performed.  
In paper III, women scheduled for LSH and TLH were included. All patients had benign 
conditions. 
Anaesthesia in the clinical trials (paper I-III) was TCI propofol and remifentanil, except from 
paper I where µg/kg/min for remifentanil infusion was used. All patients received 
paracetamol as basic pain prophylaxis.  
In paper II and III, the patients also received a NSAID either before or during surgery. Local 
anaesthesia (bupivacain) was administered in all the clinical trials. In the trials only including 
women, the patients received antiemetic prophylaxis (droperidol, ondansetron). 
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6.4 Measurement of pain 
In the three clinical trials (paper I-III), either VAS and/or VRS was used. VAS is a 100 mm 
long visual analog scale, where 0 mm corresponds to no pain, and 100 mm corresponds to the 
worst pain imaginable. VRS is a five-point verbal rating scale; 0: no pain, 1: slight pain, 2: 
moderate pain, 3: severe pain, and 4: most intense pain. 
The measurement of pain is complex (see chapter 4.5). However, we used quite simple 
methods to estimate pain postoperatively. VAS and VRS are well established methods, and 
their reliability is well documented.131-134 These methods are easy to understand and to use in 
a postoperative setting. 
In paper I-III, patients with chronic pain and/or regular use of analgesics were excluded.  
In paper I and III, PCA for postoperative pain management was used. PCA makes the 
patients more autonomous, and this can also be used to tell something about pain indirectly, 
as more pain will result in more opioid use. 
In paper II, NCA was used for postoperative pain management. In this trial, the patient had to 
ask for rescue medication or score VAS ≥ 30 mm to get opioid medication. This might be a 
more inaccurate way to treat pain, but in a day surgery unit where the patients often do not 
suffer from strong pain, it is a practical way of handling postoperative pain instead of 
cumbersome pumps and algorithms. It has been shown that with dedicated nurses, like in our 
trial, NCA is experienced as an equally satisfactory method of treating pain compared to 
PCA.135;136 
In paper III, we tried to create an “ideal” setting to avoid confounding factors with respect to 
pain. Laparoscopic hysterectomy is a standardized procedure, performed by few surgeons. In 
addition, all the patients are women at approximately the same age. Painmatcher® was used 
to discover possible differences in preoperative pain threshold between the two groups. A 
possible difference in pain threshold between the two groups would have been a confounding 
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factor. The principle of use of Painmatcher® is to grasp the left hand side electrodes between 
the left thumb and the index finger. When the patients push down the electrodes, this initiates 
a continuously ascending electrical stimulus.137 Painmatcher® has been found highly reliable 
in evaluating pre- and postoperative pain.138 In the first test, the patient had to keep the 
pressure until she felt pain (EPT- electrical pain threshold). In the second test, the patient had 
to keep the pressure to the maximum tolerable pain (maximum electrical pain threshold - 
MEPT). 
In paper IV, we induced pain in healthy volunteers. For practical reasons, a verbal rating 
scale (0-10) was used in both experimental models (electrical pain and cold pain). During the 
experiments, both hands were “tied up” - with ongoing electrical pain at one underarm, and 
the other arm exposed to ice water. The use of a linear visual analog scale would have been 
difficult, because the participant then had to use one hand to move the pointer. 
6.5 Statistical methods 
Two parallel groups were compared in the clinical trials (paper I-III). Data were analyzed 
using an independent sample t-test for parametric data, the Mann-Whitney U test for non-
parametric data and the χ2-test for categorical data. Bonferroni’s correction was performed on 
repeated pain scores values in paper I and II. In paper III, repeated measures analysis of 
variance (ANOVA) and area under the curve (AUC) were used for VAS scores. Repeated 
measures ANOVA were also used for the sedation scores in this trial.  
Paper IV was a randomized, double-blind, placebo-controlled trial with a crossover design. 
Previous trials of the electrical pain model have demonstrated that the area of pinprick 
hyperalgesia decreases from one session to another.139 Thus, data regarding areas of 
secondary hyperalgesia were normalized to achieve the same point of reference in the 
participants from all of the four treatments by setting the mean of both baseline 
measurements (15 and 30 min) of pinprick hyperalgesia after onset of electrical stimulation, 
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to 100%. The changes from this baseline were transformed to areas under the curve (AUC) 
for each period. 
We compared the infusion period (30-60 min), the postinfusion period with stimulation (60-
150 min), and the postinfusion period without electrical stimulation (150-210 min). The 
changes in percentage were not normally distributed, therefore non-parametric; two related 
samples Wilcoxon tests were performed. We also calculated the AUC of VRS scores in the 
electrical pain and the cold pressor test. These results were normally distributed, and paired 
samples T-tests for each group were performed. Paired samples T-tests were performed on 
MAP, HR and SpO2. All data were processed in the SPSS statistical software version 14.0 
and 16.0 (SPSS Inc., Chicago, IL). The significance level was set to 0.05.  
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7. Results 
7.1 Paper II and paper III 
In paper II, one hundred thirty-three women scheduled for ambulatory, laparoscopic 
gynaecological surgery were included in this randomized, double-blind study. Group E 
received etoricoxib 120 mg orally as premedication and Group K received ketorolac 30 mg 
i.v. after induction of anaesthesia. 
The first four hours postoperatively, the opioid consumption in Group K was significantly 
less than in Group E (Group K 83 ± 65 µg and Group E 123 ± 91 µg fentanyl [mean (SD), P 
= 0.004]).  
VAS was significantly lower in Group K 30 min after the end of surgery (Group K 31.3 ± 
19.7 mm and Group E 43.8 ± 16.9 mm [mean (SD), P < 0.001]). Discharge readiness was 
significantly shorter in Group K (222 ± 40 min) compared to Group E (244 ± 47 min) [mean 
(SD), P = 0.004]. There were no differences in pain scores or rescue pain medication at 24 
and 48 h postoperatively. Group E had less nausea in the 4-24 h period, 9 vs. 22 patients (P = 
0.023). 
In paper III, ninety-one women admitted for LSH or TLH were randomized to either 
intravenous oxycodone or morphine before the end of laparoscopic hysterectomy, and then 
continued with patient-controlled analgesia (oxycodone or morphine) for 24 h 
postoperatively. 
Preoperative electrical pain threshold (EPT) and maximum electrical pain threshold (MEPT) 
were similar in the two groups. 
The accumulated opioid consumption was significantly less in the oxycodone group 
compared to the morphine group; 13.3 ± 10.4 mg vs. 22.0 ± 13.1 mg (P = 0.001). The pain 
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scores were significantly lower in the oxycodone the first hour postoperatively (P = 0.037), 
and sedation was significantly lower during the 24 h postoperative period (P = 0.006). 
7.2 Paper I and paper IV 
In paper I, one-hundred patients admitted for anterior cruciate ligament (ACL) repair were 
included and randomized in a double-blind study. Group Pre received fentanyl 1.5 µg/kg i.v. 
and Group Post received placebo prior to the remifentanil infusion. At the end of surgery, 
Group Pre received fentanyl 1.5 µg/kg and Group Post received fentanyl 3.0 µg/kg i.v. 
There were no differences in postoperative pain or analgesic consumption between the two 
groups during the first four hours postoperatively. Group Post had significantly less pain in 
the 4-24 h period after surgery, with a median VRS score of ‘slight pain’ vs. ‘moderate pain’ 
in Group Pre (P < 0.05). In this period, the opioid consumption was similar in both groups. 
In paper IV, sixteen male volunteers were enrolled to demonstrate remifentanil-induced 
postinfusion hyperalgesia in an electrical pain and a cold pain model. 
Pinprick hyperalgesia (electrical pain): All groups developed stable and similar pinprick 
hyperalgesia areas during the first 30 min of electrical stimulation. During the infusion-
period, the areas under the curve (AUC) for all treatment groups receiving remifentanil were 
significantly smaller compared to AUC in the control group.  
This antihyperalgesic effect was only present during the infusion. In the postinfusion period, 
the areas of pinprick hyperalgesia exceeded control values in the remifentanil group (P = 
0.039). Pretreatment with parecoxib prevented remifentanil-induced postinfusion 
hyperalgesia compared to the remifentanil group (P = 0.044). Pretreatment with ketorolac did 
not prevent postinfusion hyperalgesia compared to the remifentanil group (P = 0.53).  
After the electrical stimulation was switched off, there were no significant differences 
between the four groups. 
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Cold pressor test (CPT): The AUC values in the first CPT (before any drugs were 
administered) were similar in all groups. The CPT at the end of the infusion demonstrated 
significantly lower VRS scores in all three groups receiving remifentanil compared to 
placebo (P < 0.001). The CPT 1 h after the end of the infusion demonstrated significantly 
higher VRS scores in the remifentanil group compared to the control group (P = 0.017). 
Pretreatment with ketorolac resulted in significantly lower VRS scores compared to the 
remifentanil group (P = 0.046). Pretreatment with parecoxib demonstrated not significant 
lower VRS scores compared to Group R (P = 0.18). 
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8. Discussion 
8.1 Paper II and paper III, different COX-inhibitors and opioids 
In these two clinical trials, different COX-inhibitors and opioids were compared in an attempt 
to improve postoperative analgesia in specific clinical models. The choice of different 
analgesic agents, included in the multimodal concept of postoperative analgesia, has become 
more patient and procedure tailored in recent years (www.postoppain.org). The choice of 
analgesics depend on several different factors. The type of surgery is an important 
determinant; the extent and type of tissue and cell damage involved, the potential of strong 
nerve stimulation or damage and the risk of bleeding. Patient related aspects are also 
important: the age and gender of the patient as well as the individual risks of specific adverse 
effects such as asthma, gastrointestinal ulcer, renal dysfunction etc. The surgical setting has 
also an impact; an inpatient will have access to intravenous administration and professional 
surveillance, this is not the case with an ambulatory patient after discharge. 
In these two studies paracetamol and local anaesthetics (bupivacain) were used to mimic a 
realistic clinical situation with new drugs administered on the top of established routines. The 
use of proper, basic non-opioid analgesics in all patient groups will reduce the need of opioid 
rescue medication and the risk of potentially serious adverse effects. However, as mentioned 
previously, this pragmatic approach may reduce the sensitivity for detecting differences 
between the study groups. 
Hypothesis paper II:  
The primary hypothesis was that etoricoxib would provide similar maximum early 
postoperative analgesia as ketorolac. The secondary hypothesis was that etoricoxib would 
provide a better analgesic effect after discharge from the hospital. 
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Presurgical injection of ketorolac 30 mg i.v. resulted in less accumulated opioid consumption 
during the first 4 h postoperatively, compared to etoricoxib 120 mg orally administered at 
least 1 h before surgery. The patients receiving ketorolac also experienced less pain at 30 min 
after the end of surgery. 
Previous studies comparing etoricoxib to non-selective or predominantly COX-1 selective 
NSAIDs in clinical postoperative pain management have demonstrated similar efficacy of the 
different drugs.27;28;140  
 Zhu et al. used an experimental model of incisional pain in rats, which would be similar to a 
postoperative clinical situation. They demonstrated significant activation of COX-1 in the 
spinal cord with incisional trauma, and less pain behaviour after preoperative intrathecal 
injection of ketorolac than of a selective COX-2 inhibitor.33;34 In most studies comparing 
non-selective NSAIDs to COX-2 inhibitors, the drugs were administered after surgery. It is 
possible that presurgical administration of a COX-1 preferring NSAID, like ketorolac, can 
slow down the central sensitization by inhibiting COX-1 in the dorsal horn of the medulla 
resulting in less pain postoperatively.33 To our knowledge three, randomized, double-blind 
studies with such preoperative administration of either a non-selective NSAID or a COX-2 
inhibitor have been conducted.141-143  
Pickering et al. compared paracetamol in combination with either rofecoxib, ibuprofen or 
placebo.143 Ibuprofen/paracetamol significantly reduced the need of early supplementary 
analgesics compared to rofecoxib/paracetamol. Pain scores were also significantly lower in 
the ibuprofen group at the time of administration of rescue pain medication. 
Morse et al.141 compared ibuprofen 400 mg vs. rofecoxib 40 mg orally as premedication for 
mandibular third molar surgery. The ibuprofen group had lower pain scores every time they 
scored the patients (not significant; n.s.), and 25% of the patients in the ibuprofen vs. 50% in 
the rofecoxib group needed rescue medication (n.s.). 
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Ng et al.142 administered ketorolac 30 mg or parecoxib 40 mg at induction of anaesthesia in 
patients undergoing laparoscopic sterilization. The pain scores were lower in the ketorolac 
group on awakening and at 1 h postoperatively, but no differences in the need of rescue 
medication were seen. 
These studies, including our work, may indicate that pretreating patients with a COX-1 
preferring NSAID before surgery may lead to lower pain scores and less need of rescue 
medication in the early postoperative phase. 
We compared one drug administered orally and one drug administered intravenously, and this 
may be criticized. Intravenous administration is a more predictable way of achieving a rapid 
and more adequate plasma concentration than oral administration. However, the oral 
medication in our trial was administered at a mean of 116 min before the start of surgery, and 
none of the patients received the tablets less than 60 min before the start of surgery, which 
would ensure full absorption and efficacy.144 However, in some of the patients anaesthesia 
actually started less than 60 min after the administration of etoricoxib. Anaesthesia per se 
may lead to delayed emptying of the stomach, and thus to a potential delayed maximum 
plasma concentration of etoricoxib in some patients. 
In paper II, the setting is ambulatory surgery where the timing aspects are crucial. The time 
from the arrival of the patient in the hospital to the start of anaesthesia and surgery is short, 
and administration of premedication at the right time is often difficult to achieve. To ensure 
that premedication tablets are completely absorbed and have maximum effect before the start 
of anaesthesia, may be important. For etoricoxib, maximum plasma concentration is reached 
after 60 min,144 but there are probably important individual differences. Even though almost 2 
h (mean) elapsed from premedication to the start of surgery in this trial, the patients receiving 
etoricoxib had more pain and needed more opioids postoperatively compared to those 
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receiving ketorolac. The administration of premedication more that two hours before the start 
of anaesthesia in a day-surgery unit is unrealistic.  
Etoricoxib 120 mg orally and ketorolac 30 mg i.v. were chosen, as these are the 
recommended maximal doses according to the approval of the Norwegian government 
medicines agency. 
For etoricoxib it has been demonstrated that no stronger effect is seen by increasing the oral 
dose beyond 120 mg in adults.140 For ketorolac, the initial dosing after marketing of the drug 
was 40-60 mg i.v as a singel dose with a possibility to repeat the dose, but after reports of 
severe adverse reactions and deaths the maximum dose was set to 90 mg i.v. /day (30 mg 
every 8th hour) in adults.145  
Surprisingly, there were no differences in pain scores or need of rescue medication at 24 h 
and 48 h postoperatively. The recommendation for ketorolac is dosing every 8 h, for 
etoricoxib every 24 h. Thus, with 2 doses of each drug administered according to the 
recommendations, ketorolac should not be expected to have efficacy throughout the first 
night and during the subsequent 24-48 h interval. The second ketorolac dose was 
administered just before discharge because of the need of an i.v. access. In our trial, that 
corresponded to 3-6 h after the first dose, and this should be even less prone to last until the 
registration at 24 h. The lack of prolonged effect of etoricoxib may be explained by a low 
baseline pain score and a low amount of rescue medication in both groups. In addition, all 
patients received paracetamol 1 g x 4 daily during the study period as a part of a basic pain 
prophylaxis. 
The etoricoxib group had significantly less nausea 24 h after surgery. This result is difficult to 
explain based on pain scores and use of rescue medication in the corresponding time period. 
It can be due to subtle non-significant differences in pain, mobilization, hydration or other 
PONV risk factors between the groups, or this result may be a coincidence. 
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We demonstrated significantly less time to discharge from the hospital in the ketorolac group 
compared to the etoricoxib group. We interpret this as a result of less pain and less need of 
opioid rescue medication in the ketorolac group during this part of the postoperative periode. 
Hypothesis paper III:  
The main hypothesis was that oxycodone and morphine were equipotent analgesics in a study 
of clinical visceral pain, in terms of doses measured in mg and with similar effect/adverse 
effect profile.   
In this clinical model of visceral pain, the patients in the oxycodone group needed 
significantly less accumulated oxycodone compared to the accumulated morphine 
consumption in the morphine group (13 mg vs. 22 mg). This 2:3 ratio between oxycodone 
and morphine has been demonstrated previously in an other clinical model of visceral pain.44 
In contrast, clinical studies comparing these two drugs in a postoperative setting with both 
somatic and visceral pain have found a 1:1 ratio.42;43 
Our findings are supported by experimental studies in humans, which confirm that 
oxycodone is superior to morphine in visceral pain.45;46 
Oxycodone is clearly a µ-receptor agonist, as discribed in chapter 4.3., table 1. Studies in rats 
suggest that oxycodone also has κ-opioid receptor agonist properties,146-148 even though this 
is highly disputed,149 and not demonstrated in humans. The κ-opioid receptor is involved in 
visceral pain,150;151 and if oxycodone has κ-opioid receptor agonist properties this may 
explain why oxycodone has some advantages in the treatment of visceral pain compared to 
morphine. 
In addition, we found a significantly longer time to the first PCA oxycodone request after the 
end of surgery. Based on this, we may conclude that the effect of the first standard dose of 
oxycodone administered by the end of surgery lasts longer, or that the drug is more potent, or 
both. 
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Oxycodone’s affinity to the μ-opioid receptor is > 20 times less than morphine.49 
The oxycodone concentration needed to activate the G-protein as measured by the [35S]GtyS 
agonist-stimulated binding is 3-8 times higher compared to morphine.49;50 In spite of this, in 
our trial it seems that oxycodone is more potent than morphine, and has less adverse effects 
in terms of less sedation. 
Recent studies in rats indicate that oxycodone is actively transported through the BBB 
(blood-brain barrier).67;68 With the same unbound blood concentrations of oxycodone and 
morphine, the unbound concentration of oxycodone in the brain is six times higher than 
morphine.68 
This may explain why oxycodone seems to be more potent than morphine, but it does not 
explain the different ratio between oxycodone and morphine in patients undergoing surgery 
with mainly visceral pain compared to patients undergoing surgery with both somatic and 
visceral pain.  
The first hour postoperatively, the pain scores were significantly lower in the oxycodone 
group in spite of the use of PCA. This may again be explained by the possibility that 
oxycodone might be more potent that morphine in visceral pain, or that the onset of analgesia 
in the morphine group after PCA dosing is slower. Morphine is generally considered to be a 
slow-acting drug, but the few clinical studies on this issue suggest a fairly similar time to 
onset (about 5-8 min) and peak effect (about 20-30 min) for both drugs administered as i.v. 
bolus.152;153 In a clinical postoperative pain study, Kalso et al. demonstrated that oxycodone 
achieved faster pain relief and lasted longer than morphine.44 This is in accordance with our 
results, indicating a faster onset of analgesia with oxycodone than morphine. 
After two hours the differences in pain scores between the oxycodone and morphine groups 
disappeared. As oxycodone passes the blood-brain barrier faster than morphine,67;68 this 
might explain the gap between pain scores during the first postoperative hour. As morphine 
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slowly penetrates into the CNS, it would take some time before the pain scores are reduced to 
the same level as in the oxycodone group.  
8.2 Paper I and paper IV, opioid-induced hyperalgesia 
Opioid-induced hyperalgesia might influence postoperative pain in terms of stronger pain and 
a higher need of analgesics.107-109;111 It is therefore important to explore different approaches 
to reduce OIH.  
Paper I did not elucidate OIH development, as there was no control group with less potential 
of developing OIH. To demonstrate that these patients actually developed OIH/acute 
tolerance, a third group with inhalation anaesthetic instead of opioid, or on top of low-dose 
opioid should have been included. However, when considering the induction of OIH after 
only 30 min of low dose remifentanil in paper IV, it is likely that the patients in both our 
groups in paper I developed OIH as they received high doses of remifentanil for 
approximately 90 min. 
Hypothesis paper I: 
Pretreatment with fentanyl before induction of remifentanil-based anaesthesia would 
decrease the self-rated pain scores and opioid consumption in the postoperative period. 
The idea of pretreatment with one opioid before using another opioid during anaesthesia to 
avoid OIH/acute tolerance was based partly on studies on opioid rotation in cancer 
patients,71;120 as described in chapter 4.4. Opioid rotation of pure agonists has been 
demonstrated to be successful strategies in decreasing OIH.154  
The question remains as to whether the use of a pure opioid agonist, with different receptor-
binding properties and a longer duration of action than remifentanil, would be beneficial in 
this context. The initiation of study I was also encouraged by widespread, non-documented 
practice in many Norwegian departments to administer fentanyl before remifentanil in order 
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to reduce the remifentanil dose, smoothen the recovery and potentially reduce opioid-induced 
hyperalgesia. 
We did not manage to demonstrate reduced postoperative pain or rescue opioid consumption 
after remifentanil-based anaesthesia when pretreating the patients with fentanyl 1.5 µg/kg i.v. 
This negative result may be due to the fact that the dose of fentanyl was too low. The 
pretreatment dose of 1.5 µg/kg did not have any effect on remifentanil consumption during 
surgery compared to the group which did not receive fentanyl before start. The higher 
fentanyl dose (Group Pre: 1.5 µg/kg vs. Group Post: 3.0 µg/kg) at the end of surgery resulted 
in less pain 24 hours postoperatively in Group Post, which is beyond the expected duration of 
effect from such a dose. One explaination may be a potentially better immediate analgesic 
protection with the higher dose, which reduce the wind-up and activation of pain 
enhancement mechanisms otherwise seen in the postoperative period. 
Changing from phenantren to peperidin derivatives has been suggested as a treatment to 
reduce OIH.71 McDonnell et al. tried to pretreat patients with morphine (phenantren 
derivative) 150 µg/kg before remifentanil (peperidin derivative)-based anaesthesia. They did 
not manage to demonstrate reduced pain scores or analgesic consumption postoperatively, 
even though morphine is a longer-acting opioid compared to fentanyl.155  
Paper I demonstrates that the practice of pretreating the patients with low-dose fentanyl has 
no beneficial impact on postoperative pain or analgesic consumption. 
Hypothesis paper IV:  
The main hypothesis was that remifentanil would induce postinfusion hyperalgesia in both 
experimental models. The secondary hypothesis was that parecoxib and ketorolac would 
prevent or diminish this postinfusion hyperalgesia in both experimental models. 
Two different experimental models (electrical model and cold pressor model) were used to 
demonstrate OIH. As NSAIDs are widely used in clinical postoperative pain, it is interesting 
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to investigate whether these drugs can prevent OIH, as OIH may increase postoperative pain 
and analgesic consumption. 
Parecoxib, a relatively selective COX-2 inhibitor,156 blocked the opioid-induced enlargement 
of a hyperalgesic area, suggesting that OIH may be stimulated by spinal COX-2 activity in 
humans.102 
Both COX-1 and COX-2 are expressed in the spinal cord.34;157;158 There is growing evidence 
suggesting that spinal COX-inhibition plays an important role in producing antinociception 
and reducing hypersensitivity.34;88;159 There is also evidence for an up-regulation of 
prostaglandin E2 in the CNS after surgery.88;160 Therefore, spinal COX-inhibition may be of 
importance in preventing acute hyperalgesia after surgery. It would be of interest to 
investigate whether a COX-1 preferring inhibitor, like ketorolac,161 also would reduce OIH. 
The timing of the administration of a COX-inhibitor seems to be important in reducing OIH. 
Parecoxib was either administered just before remifentanil infusion or approximately 30 min 
before remifentanil infusion in the study of Tröster et al.102 Only the parecoxib dose 
administered 30 min before infusion reduced the postinfusion hyperalgesia.102  
Therefore, in our study, ketorolac and parecoxib were administered 15 min before the 
electrical stimulus was switched on, and 45 min before remifentanil infusion (fig. 1 in paper 
IV). Ketorolac 30 mg i.v. and parecoxib 40 mg i.v. were chosen, as these are the 
recommended maximum doses according to the approval from the Norwegian government 
medicines agency. 
This trial demonstrated that remifentanil induced postinfusion hyperalgesia in both 
experimental pain models (electrical pain and cold pain). 
Administration of parecoxib before remifentanil infusion, prevented remifentanil-induced 
hyperalgesia only in the electrical pain model. This has been demonstrated in an previous 
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study.102 Surprisingly, ketorolac prevented remifentanil-induced hyperalgesia only in the cold 
pain model. 
While the cutaneous hyperalgesia is mediated by cutaneous “silent” mechano-insensitive C-
nociceptors,162 the cold pressor pain is mediated by nociceptors in the veins.163 
This different peripheral activation may explain the different effect of the two NSAIDs in the 
two modalities.  
The pain scores in the cold pressor test (postinfusion) are relatively similar between 
parecoxib and ketorolac, even though only the pain scores in the ketorolac group were 
significantly lower compared to the remifentanil group. These results may suggest that COX-
2 rather than COX-1 inhibition may be most important in reducing opioid-induced central 
sensitization in these models of experimental pain. However, we do not know to which extent 
these experimental pain models can be extrapolated to a situation with clinical postoperative 
pain.  
It is also interesting to note that hyperalgesia was produced with a fairly low dose of 
remifentanil administrated for a short period. Although this was an experimental model, the 
results may be added to the ongoing discussion as to how much and how long remifentanil 
needs to be administered during clinical anaesthesia for significant hyperalgesia to develop. It 
is also interesting to note that in our experimental model the hyperalgesia was shortlasting 
(fig. 4 paper IV) and modest. Thus, the impact on pain in a clinical postoperative situation 
may not be evident or measurable unless a very sensitive and non-confounding study design 
is employed. 
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9. Conclusions 
9.1 Paper II and paper III 
In paper II, administration of ketorolac 30 mg i.v. before the start of surgery resulted in 
significantly less pain 30 min after the end of surgery, significantly less opioid consumption 
during the first 4 h postoperatively, and significantly faster postoperative discharge readiness 
compared to oral etoricoxib 120 mg administered as premedication. 
With a repeated dose of ketorolac before discharge, there were no differences in pain or 
rescue analgesic consumption until the next day. Administration of etoricoxib 120 mg in 
Group E at 24 h postoperatively did not reduce pain scores or need of rescue medication in 
the subsequent 24-48 h period compared to ketorolac, but less nausea was observed in the 4-
24 h period. Thus, in terms of clinical analgesic effect there is no rationale to change from 
ketorolac to etoricoxib, although other aspects of adverse effects, costs and mode of 
administration are also valid in this context. 
In paper III, the accumulated oxycodone consumption was significantly lower compared to 
the accumulated morphine consumption. In addition, the oxycodone group had less pain 
during the first postoperative hour, and was less sedated throughout the entire postoperative 
period. It is our conclusion that PCA oxycodone is a better alternative than PCA morphine in 
terms of clinical analgesic effect and less sedation after this kind of procedure. 
9.2 Paper I and paper IV 
Pretreatment with fentanyl 1.5 µg/kg i.v. (Group Pre) did not reduce postoperative pain or 
analgesic consumption (0-4 h) after 90 min of remifentanil-based anaesthesia with 
remifentanil 0.43 µg/kg/min. Group Post had significantly less pain in the 4-24 h period after 
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surgery, with a median VRS score of ‘slight pain’ vs. ‘moderate pain’ in Group Pre (P < 
0.05). The oxycodone consumption was similar in both groups. 
We conclude that there is no rationale to use low dose fentanyl as pretreatment before 
remifentanil infusion in this setting, but rather that fentanyl should be administered in an 
adequate dose at the end of the surgical procedure. 
In paper IV, postinfusion remifentanil-induced hyperalgesia was demonstrated in both 
experimental pain models. Parecoxib prevented hyperalgesia in the electrical model, and 
ketorolac prevented hyperalgesia in the cold pressor test. Our results may suggest that COX-2 
rather than COX-1 inhibition is of major importance to reduce opioid-induced central 
sensitization.  
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10. Future perspectives 
10.1 NSAIDs 
Non-selective NSAIDs and COX-2 inhibitors have been investigated in a large number of 
studies with respect to perioperative analgesia. In 2009, Scott Reuben, a leading investigator 
was disclosed for data fabrication,164 and a large number of his articles has been retracted.165 
Several of Reuben’s works are of controversial topics related to NSAIDs and COX-2 
inhibitors. 
Reuben has reported that NSAIDs may have a preemptive effect, but this has been questioned 
by other investigator groups.37 Further studies are therefore needed to either disprove or 
certify this allegation. 
The clinical effect of NSAIDs and COX-2 inhibitors on bone and tissue healing is another 
important topic that needs clarification. One of Reuben’s articles demonstrated no differences 
in the bone fusion rate after 1 year, with the use of perioperative celecoxib.166 This topic 
needs more investigation even though another group have also demonstrated no differences in 
bone fusion rates with the use of ketorolac.167 
The role of NSAIDs and multimodal analgesic regimens in preventing chronic pain after 
orthopaedic surgery also remain unsettled,4;168 and needs further studies. 
10.2 Oxycodone 
Oxycodone is an old opioid which has gained new interest during the last decade.41 Its 
possible superior effect in visceral pain has particularly been investigated.45;46 Human studies 
have clearly demonstrated that oxycodone is a selective µ-opioid receptor agonist,49;50;169 but 
its affinity to the µ-opioid receptor is 20 times less than the affinity of morphine.49 Based on 
this, it is difficult to explain that oxycodone and morphine have approximately the same 
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potency in different clinical settings. A Swedish group has demonstrated a potential active 
transport mechanism of oxycodone through the BBB,67;68 which may in part explain this gap 
between the weak affinity to the µ-opioid receptor and oxycodone’s potency in the clinic. 
However, it does not explain the different ratio between oxycodone and morphine in patients 
undergoing visceral surgery vs. somatic surgery.43;44;52 Whether this is a real difference or 
not, is difficult to conclude from these studies, as they have quite different design. 
To rule out this doubt, a future study comparing morphine and oxycodone should actually 
contain two clinical trials with equal design. One study with somatic pain postoperatively and 
one study with visceral pain postoperatively.  
10.3 Opioid-induced hyperalgesia 
The strongest evidence that opioids induce hyperalgesia in humans originates from studies of 
healthy volunteers exposed to opioid infusion.121 The main problem is to demonstrate OIH in 
clinical studies, where there might be a lot of confounding factors compared to the controlled 
situation in an experimental design. We also need to get a better understanding of which 
experimental pain models that are most relevant for clinical post-surgical pain. It is also 
important to document the potential clinical implications of OIH. The main challenge in the 
future is do develop a good model being able to differentiate OIH from acute tolerance in a 
clinical setting. If this is achieved, we would hopefully be able to develop different types of 
clinical interventions to reduce or avoid OIH.    
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 2 
Abstract 
Background: Opioids may enhance pain sensitivity, called opioid-induced hyperalgesia 
(OIH). Spinal cyclooxygenase activity may play a role in the development of OIH. The aim 
of this study was to demonstrate remifentanil-induced postinfusion hyperalgesia in an 
electrical pain and a cold pain model. We also investigated if pretreatment with parecoxib or 
ketorolac could prevent remifentanil-induced hyperalgesia. 
Methods: Sixteen healthy males were enrolled in this randomized, double-blind, placebo-
controlled study in a crossover design. Each subject went through four sessions: control, 
remifentanil, parecoxib + remifentanil and ketorolac + remifentanil. Each session started with 
a cold pressor test (CPT). The subjects received a bolus of either saline, parecoxib 40 mg or 
ketorolac 30 mg intravenously. Transcutaneous electrical stimulation induced acute pain and 
stable areas of pinprick hyperalgesia, which were assessed before, during and after a 30-min 
infusion of either remifentanil or saline. The CPT was repeated at the end of the infusion and 
one hour thereafter. 
Results: The areas of pinprick hyperalgesia were reduced during the infusion of remifentanil, 
but increased significantly thereafter. Pretreatment with parecoxib prevented this enhanced 
postinfusion area of hyperalgesia, but ketorolac did not. Pain ratings in the CPT one hour 
after ended infusion of remifentanil were significantly higher compared to control. 
Pretreatment with ketorolac prevented these enhanced pain scores, but parecoxib did not.  
Conclusions: Postinfusion remifentanil-induced hyperalgesia was demonstrated for both the 
electrically induced pain and the cold pressor pain. Parecoxib prevented hyperalgesia in the 
electrical model, and ketorolac prevented hyperalgesia in the CPT.  
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Introduction 
Opioids are the cornerstone in the treatment of moderate to severe pain. In addition to 
alleviate pain, there is growing evidence that μ-opioids may reduce the pain threshold, 
resulting in enhanced pain when the opioid effect diminishes after end of administration.1-5 
This phenomen is known as opioid-induced hyperalgesia (OIH). Large doses of μ-opioids 
during surgery seem to enhance pain after emergence from anesthesia and the patients need 
more opioids postoperatively.6-8 
Activation of the N-methyl-d-aspartate (NMDA)-receptor complex by μ-receptor agonists 
seems to be one underlying mechanism of this hyperalgesia development,4,9,10 and OIH can 
be prevented by administrating ketamine, an NMDA receptor antagonist.2,4,5,11 
Prostaglandins, like PGE2, can stimulate glutamate release from astrocytes and from the 
spinal cord dorsal horns with subsequent activation of the NMDA receptors.12,13 
Subsequently, cyclooxygenase inhibitors were found to antagonize this NMDA receptor 
activation.14,15 Since the NMDA receptor is involved in OIH, it may be possible to reduce 
OIH by cyclooxygenase (COX) inhibitors. Parecoxib, a relatively selective COX-2 
inhibitor,16 blocked the opioid-induced enlargement of a hyperalgesic area, suggesting that 
OIH may be stimulated by spinal COX-2 activity in humans.17 Both the COX-1 and COX-2 
variant of the COX-enzyme are expressed in the spinal cord, and COX-1 activation has also 
been shown to be important in pain development after surgery.18-20 Therefore, it would be of 
interest to investigate whether a COX-1 preferring inhibitor, like ketorolac,21 also could 
reduce OIH. 
In this study we investigated whether parecoxib and ketorolac could prevent OIH. We used 
two different experimental pain models; one model using electrical stimulation to induce pain 
and secondary mechanical hyperalgesia22,23 and another model inducing pain from cold 
stimuli (cold pressor test - CPT).24  
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The cold pressor pain has been shown to be opioid sensitive.25 By adding CPT as a second 
pain stimulus, we wanted to study whether postinfusion hyperalgesia also include acute pain 
ratings to this tonic, painful stimulus and could be modulated by COX-antagonists.
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Materials and Methods 
The protocol of this randomized, double-blind, placebo-controlled study with a crossover 
design in volunteers was reviewed and approved by the Regional Committee for Medical 
Research Ethics in Eastern Norway and the Norwegian Medicines Agency. The study was 
registered in ClinicalTrails.gov (ID: NCT 00785863). 
Sixteen healthy male subjects were enrolled. None of the subjects had any known drug 
allergy or used any other kind of medication before or during the experiments. Alcohol or 
drug abuse were exclusion criteria. All subjects were familiarized with the experimental 
models by a pre-study session. 
To provoke pain and secondary hyperalgesia we used a well established intra-dermal 
electrical pain model.2,4,17,22 This model has been proven to create a stable area of secondary 
hyperalgesia to punctate stimuli by an activation of primarily mechanoinsensitive “silent” C-
nociceptors.23 These nociceptors are activated at high current densities.26 
Two microdialysis fibers equipped with internal stainless steel wires were inserted 
intradermally in the central volar forearm. The intradermal length of each fiber was 
approximately 10 mm, and the distance between the fibers about 5 mm. 
We applied monophasic, rectangular electrical pulses of 0.5 ms duration with alternating 
polarity via a constant current stimulator, Digitimer DS7A (Digitimer, Hertfordshire, UK) at 
2 Hz. The current intensity was gradually increased during the first 15 min of the stimulus 
administration to induce a pain score of 6 on a verbal rating score (VRS) going from 0 to 10 
(0 = no pain, 10 = worst pain imaginable). The subjects were allowed to use a decimal to 
indicate one level between integers (i.e. 0.5, 1.5, etc.), making it a 21-points scale. 
The current was adjusted so that the subject scored VRS = 6 after 15 min, and this current 
intensity was kept constant for the rest of the stimulation period; totally 150 min (fig. 1). 
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Each subject went through four separate sessions with an interval of at least one week 
between each session. 
The control group (Group C) received a 0.9% NaCl bolus intravenously and an infusion of 
0.9% NaCl (fig. 1). The remifentanil group (Group R) received a 0.9% NaCl bolus 
intravenously and an infusion of remifentanil. The parecoxib + remifentanil group (Group 
PR) received a 40 mg parecoxib bolus intravenously and an infusion of remifentanil. The 
ketorolac + remifentanil group (Group KR) received a 30 mg ketorolac bolus intravenously 
and an infusion of remifentanil. 
10 ml syringes for bolus of 0.9% NaCl, parecoxib or ketorolac were used. The parecoxib and 
ketorolac syringes were diluted with 0.9% NaCl, so all syringes contained the same amount 
of clear liquid (10 ml). 
The infusion time of remifentanil or saline was 30 min. 50 ml syringes with the same amount 
of clear liquid were used. We used TCI-effect site target control infusion, Minto-model,27,28 
starting with 1.0 ng/ml for the first 2 min, thereafter 2.5 ng/ml for the rest of the infusion time 
of 30 min (fig. 1). By using effect-TCI we reached a steady-state level faster than using 
µg/kg/min infusion, which earlier studies have used.2,4,17 
During the infusion of remifentanil or 0.9% NaCl the investigator asked about possible opioid 
side effects (e.g. nausea, dizziness, pruritus).  
Non-invasive blood pressure, electrocardiography and pulse oximetry were monitored 
continuously during the study. 
During the ongoing electrical pain stimulus, the subjects scored VRS every 5 min. In 
addition, the area of pinprick-hyperalgesia was determined by using a 26 g von Frey filament. 
The hyperalgesia areas were determined by measuring in four linear paths parallel and 
orthogonally to the axis of the forearm from distant starting points toward the stimulation site 
(step size 5 mm), until the subject reported increased pain sensation. In the measuring of the 
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area of secondary hyperalgesia, both diameters (D/2 × d/2 × π) were used. Area of secondary 
hyperalgesia was determined every 15 min, from the start of the electrical stimulation (time = 
0 min) until one hour after the end of the electrical stimulation period (210 min).  
The subjects also underwent the CPT,24 and pain was reported using VRS, as in the electrical 
pain model. They performed 3 CPTs for each of the four sessions: one test before any drugs 
were administered, one test just before the end of the remifentanil/saline infusion, and one 
test one hour after the end of the remifentanil/saline infusion (fig. 1). The last CPT was 
performed one hour after the end of the infusion, because presumably there should be 
virtually no remifentanil left in the circulation or in the brain, based on the elimination 
algorithm in the Minto model.27,28 
The water in the CPTs had a temperature between 0.5-1.5 °C. The hand was kept in the water 
for a maximum of 120 sec at each test. The subjects were asked to score pain (VRS) every 10 
sec. If the subject was unable to keep the hand in the water for 2 min (the pain was 
unbearable), the rest of the values were scored to 10. 
 
Statistics 
Sample size was calculated based on results from a previous study on area of post-infusion 
hyperalgesia.17 Assuming a SD for the difference between treatments of 10%, a paired t-test 
(alfa = 0.05, two-sided) with 16 paired observations would yield 96% power to detect a mean 
difference of 10% , and 80% power to detect a difference of 7.5% (SamplePower 2.0). Based 
on these calculations, we decided to include 16 subjects.  
Earlier studies using this electrical pain model have demonstrated that the area of pinprick 
hyperalgesia decreases from one session to another session despite the same intensity in 
electrical stimulation and pain ratings.29 
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Therefore, data regarding areas of secondary hyperalgesia were normalized to achieve the 
same point of reference in subjects from all of the four treatments by setting the mean of both 
baseline measurements of pinprick hyperalgesia, i.e. 15 and 30 min after onset of electrical 
stimulation, to 100%. The changes from this baseline were calculated as areas under the 
curve (AUC) for different time periods. 
We compared the infusion period (30-60 min), the postinfusion period (60-150 min), and the 
postinfusion period without electrical stimulus (150-210 min). The areas under the curve for 
change in area of hyperalgesia (percentage changes) were not normally distributed, therefore 
non-parametric, two-sided Wilcoxon tests were performed.  
AUC of VRS for the electrical pain and the CPT were also calculated. These results were 
normally distributed, and paired samples T-tests for each group were performed. 
Paired samples T-tests were performed on MAP, HR and SpO2. 
Data were analyzed in SPSS 16.0. The significance level was set to 0.05. 
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Results 
All subjects participated in all sessions as planned without dropouts or interfering medication.  
There were no correlation between mean electrical current (mA) needed for VRS = 6 after 15 
min and mean VRS for the first cold pressor test in the individual test person (P = 0.52, by 
Pearson correlation test). 
 
Side effects and vital function monitoring values 
The vital function monitoring values (SpO2, MAP and HR) are shown in fig. 2. All subjects 
developed side effects during remifentanil infusion (table 2). The side effects never interfered 
with the subjects’ ability to answer the questions from the investigators.  
Mean arterial blood pressure measured just after the second CPT increased significantly 
compared to MAP measured before the CPT in Group C, but the increase was significantly 
reduced in the three groups receiving remifentanil (fig. 2). The post-infusion CPT (third CPT) 
induced unchanged blood pressure increase in Group C, but in Group R and Group PR the 
increase remained significantly lower. Only in Group KR the blood pressure increased to a 
similar level as in Group C (fig. 2). 
 
Pain ratings 
To achieve a pain rating of VRS 6, the average current was increased to 31.2 ± 22.5 mA 
(mean ± SD) during the first 15 min of the electrical stimulation (table 1). After keeping the 
current constant, the pain ratings decreased significantly at 30 min, to VRS 5.1 ± 0.07 (mean 
± SEM). No significant differences were found between the four groups (fig. 3).  
During infusion of remifentanil/saline, the pain ratings decreased significantly in the groups 
receiving remifentanil compared Group C (control), P < 0.001 for all three groups (fig. 3). 
There were no significant differences in VRS between the three groups receiving remifentanil 
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during the 30 min of infusion. After the end of the infusion, the pain ratings increased and 
reached control values. In the Group KR (ketorolac + remifentanil), the pain ratings (VRS) 
exceeded the ratings in Group C and became significantly higher during the rest of the 
electrical stimulation (P = 0.036, by paired samples T-test).  
 
Pinprick hyperalgesia 
All groups developed stable pinprick hyperalgesia areas during the first 30 min of the 
electrical stimulation. The areas measured 65.3 (10.9) cm2 in Group C, 71.2 (8.2) cm2 in 
Group R, 73.3 (5.9) cm2 in Group PR and 72.7 cm2 (6.9) in Group KR (mean ± SEM). There 
were no significant differences between the groups (paired samples T-test). 
During the remifentanil/saline infusion-period the areas under the curve (AUC) for all three 
treatment groups receiving remifentanil became significantly smaller compared to control (P 
< 0.001 in Group PR and Group KR, P = 0.025 in Group R, fig. 4). There were no significant 
differences between the groups receiving remifentanil, albeit the reduction of hyperalgesic 
areas appeared to be more pronounced when COX-inhibitors were co-administered. 
This antihyperalgesic effect was only present during the infusion. After the end of the 
infusion, the areas of pinprick hyperalgesia exceeded control values in Group R, P = 0.039 
(60-150 min – post infusion period). Pretreatment with parecoxib prevented postinfusion 
remifentanil-hyperalgesia compared to Group R, P = 0.044. Pretreatment with ketorolac did 
not prevent postinfusion hyperalgesia compared to Group R, P = 0.53.  
After the electrical stimulation was switched off (150-210 min – stop electric stimulus 
period), there were no significant differences in the areas of pinprick hyperalgesia between 
the four groups (fig. 4). The remifentanil induced hyperalgesia (Group R) has returned to 
baseline values (Group C). 
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Cold pressor test 
The AUC values of the first CPT (before any drugs were administered) remained similar 
between all sessions (fig. 5A). In the Group C, there were no significant differences between 
the three consecutive CPTs.  
The CPT at the end of the infusion (second CPT) demonstrated similar and significant lower 
VRS in all three groups receiving remifentanil compared to second CPT in Group C (P < 
0.001, fig. 5B).  
The CPT 1 h after the end of infusion showed significantly higher VRS in Group R compared 
to Group C (P = 0.017, fig. 5C). Pretreatment with ketorolac (Group KR) resulted in 
significantly lower VRS compared to Group R (P = 0.046), whereas pretreatment with 
parecoxib did not (P = 0.18). 
There were no significant differences between Group C, Group PR and Group KR at the third 
CPT.  
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Discussion 
We were able to reproduce significant hyperalgesia after cessation of a 30 min infusion of 
remifentanil as assessed by increased area of secondary mechanical hyperalgesia as 
demonstrated in earlier studies.2,4,17 In parallel, pain ratings to noxious cold stimuli increased 
in the remifentanil group compared to control, reflecting hyperalgesia in the cold pressor test.  
Increased pain after cessation of opioid application can be interpreted as acute tolerance or 
OIH.1 The duration of remifentanil application in our study was too short to investigate 
tolerance.30 Previous studies in healthy volunteers did not observe remifentanil-induced 
tolerance even at application times of 90 min.2 Thus, in our study, post-infusion hyperalgesia 
developed as measured by pain ratings to electrical stimulation and area of secondary 
mechanical hyperalgesia. Hyperalgesia for electrical pain has been demonstrated previously,2-
4,17 but not for heat stimuli.2 
While confirming that remifentanil induced increase of secondary mechanical hyperalgesia, 
we additionally found post-infusion hyperalgesia in the CPT, as might have been expected 
according to previous results.30,31 
Our results confirm that low-dose remifentanil (target 2.5 ng/ml) and short infusion (30 min) 
result in detectable hyperalgesia. However, the magnitude of hyperalgesia seems to be limited 
and the duration shortlasting, as the areas of hyperalgesia returned to control values after the 
electrical pain was swift off (fig. 4).  
Opioid-induced NMDA activation or internalization of µ-opioid receptors have been 
suggested as the etiology of OIH.32 
Recently, intracellular recordings of dorsal horn neurons have shown that withdrawal of 
remifentanil can acutely induce long-term potentiation (LTP) in spino-thalamic tract 
projection neurons that was sensitive to NMDA blockers.33 Increased pain ratings to CPT and 
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electrical stimuli as well as larger areas of secondary mechanical hyperalgesia are in 
accordance with these results. 
Administering parecoxib before remifentanil infusion, prevented remifentanil induced 
hyperalgesia only in the electrical pain model. This has been demonstrated in an earlier 
study.17 Surprisingly, ketorolac prevented remifentanil induced hyperalgesia only in the cold 
pain model. 
The secondary mechanical hyperalgesia is induced by sensitizing spinal input from “silent” 
mechano-insensitive C-nociceptors,26 that renders the dorsal horn hypersensitive to A-delta 
nociceptor input.34 In contrast, the cold pressor pain is mediated by tonic discharge of 
nociceptors in the veins.35 This different peripheral activation may explain the different effect 
of the two NSAIDs on the two modalities.  
Both COX-1 and COX-2 are expressed in the spinal cord.18-20 There is growing evidence 
suggesting that spinal COX-inhibition plays an important role in producing antinociception 
and reducing hypersensitivity.14,18,36,37 There is also evidence for an up-regulation of 
prostaglandin E2 in CNS after surgery.14,38 Therefore, spinal COX-inhibition may be of 
importance in preventing acute hyperalgesia after surgery. 
So far, there are few studies on OIH in a clinical incision pain model, but one study 
demonstrated increased pain sensitivity assessed by peri-incisional allodynia and 
hyperalgesia after large-dose intraoperative remifentanil.11 In that study ketamine prevented 
peri-incisional allodynia and hyperalgesia.  
To our knowledge no clinical study has tried to do the same with a COX-inhibitor. However, 
one study has demonstrated that lornoxicam, a combined COX-1 and COX-2 inhibitor, 
significantly diminished the acute opioid tolerance and/or hyperalgesia caused by fentanyl.39 
The ratings of electrically induced pain after end of remifentanil infusions in the study from 
Tröster et al.17 exceeded the pain scores compared to their control group. This hyperalgesic 
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effect remained stable for the rest of the observation period. We could only demonstrate this 
hyperalgesic effect in the ketorolac group (fig. 3). We hypothesize that the CPTs may have 
disturbed the pain ratings from the electrical pain scores, accordning to the classical gate-
theory.40 The CPT is a painful test, and many of the subjects had considerably lowered scores 
from the stable electrical pain stimulation after the CPTs.  
An interesting observation is that, in addition to higher electrical pain scores in Group KR 
after remifentanil-infusion, this group also had a significantly higher MAP after the last CPT 
compared to Group PR and Group R (fig. 2). Blood pressure control and descending pain 
inhibition share common pathways and mechanisms in a complex and not fully understood 
way. The fact that the ketorolac group had higher MAP after the last CPT (DNIC-diffuse 
noxious inhibitory control-procedure) and higher electrical pain scores after infusion 
compared with the remifentanil and the parecoxib group indicates that ketorolac may block 
descending inhibition induced by cold pressor test and that mechanisms shared with blood 
pressure control is involved (eg. NA-mechanisms).   
There was no correlation between mean electrical current (mA) needed for VRS = 6 after 15 
min and mean VRS for the first cold pressor test in the individual test person. This is in 
accordance with results from an animal study, which demonstrates a lack of correlation of 
sensitivity to nociception in different pain models.41  
An important question is the relevance of our results for clinical postoperative pain. The 
measurement of pain to cold-, electrical-, heat- and pressure-stimuli are only experimental 
tests that will not ideally mimic clinical pain conditions; on the other hand, using surgical 
incision is un-feasible in volunteers. 
An animal, incisional pain model was linked to spinal COX-1 activation,18 whereas COX-2 
was activated in an inflammatory pain model.42 Comparable data from humans do not exist. 
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Certainly more research should be done in this area, preferably with clinical models of real 
surgical pain.  
In conclusion, we have demonstrated postinfusion remifentanil-hyperalgesia in electrically 
induced pain and cold pressor pain. Our results may suggest that COX-2 rather than COX-1 
inhibition is of major importance to reduce opioid-induced central sensitization.  
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Table 1  
Age, weight, height and mean electrical current  
in the four sessions of the subjects.  
 
No.                 Age, yr     Weight, kg     Height, cm            Current, mA    
1                    31                70                 177                  28.6 ± 21.7       
2                    24                93                 188                  18.2 ± 6.4 
3                    35              100                 179                  68.3 ± 17.3 
4                    35                88                 189                  83.9 ± 14.4   
 5                        22                94                 194                  14.3 ± 4.5 
 6                        41                78                 181                  15.6 ± 1.8 
 7                        24                92                 189                    5.8 ± 2.0 
 8                        23                83                 185                  46.4 ± 10.8 
 9                        24                94                 173                  42.4 ± 4.1 
10                       25                62                 173                  40.2 ± 16.3 
11                       29                74                 187                  15.3 ± 3.1 
12                       27                80                 174                  26.6 ± 3.1 
13                       50              112                 190                  30.2 ± 6.0  
14                       21                79                 189                  34.2 ± 2.5 
15                       26                63                 179                  12.2 ± 3.8 
16                       22                73                 173                  17.0 ± 2.9 
Mean ± SD    29 ± 8          83 ± 14          183 ± 7               31.2 ± 22.5 
 
Data are presented as (mean ± SD). 
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Table 2 
Side effects during drug infusions. 
                     Saline     Remifentanil     Parecoxib + Remifentanil      Ketorolac + Remifentanil  
Sedation               0                    14                                 11                                          12                 
Pruritus                0                    10                                   9                                            8 
Nausea                 0                      1                                   3                                            1 
Dizziness           0                      6                                   7                                            9             
 
Number of subjects who reported side effects (n = 16). 
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Fig. 1. Schematic illustration of the experimental protocol. Four treatments were performed in a randomized 
order on each subjects. Every treatment started with a cold-pressor test (CPT, [--]). The subjects then received 
an intravenous bolus of either 0.9% NaCl, 30 mg ketorolac or 40 mg parecoxib (■). The electrical stimulus 
started 15 minutes after the bolus. After 30 minutes of electrical stimulus a 30 minutes-infusion of 0.9% NaCl or 
remifentanil was carried out. At the end of each infusion and one hour after the end of infusion, a CPT was 
performed. The electrical stimulus was on for 150 minutes. Pinprick hyperalgesia was performed every 15 
minutes, from 15 minutes after start of electrical stimulus to one hour after the end of electrical stimulus. 
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Fig. 2. Infusion of remifentanil resulted in a significant decrease in oxygen saturation (SpO2), * P < 0.001. Mean 
arterial pressure (MAP) measured just after the second and third cold pressor test (CPT) had a significant 
increase in all groups compared to MAP measured before each CPT. Group C (control) had an increase in mean 
MAP of 12 mmHg (* P = 0.001) and 14 mmHg (* P < 0.001) after the second and third CPT respectively. The 
three groups receiving remifentanil had an increase in mean MAP of 4 mmHg (* P = 0.002) after the second 
CPT. Group C had a significant higher increase in MAP compared to the three groups receiving remifentanil, * 
P = 0.03.  
After the last CPT, MAP remained significantly lower in Group R (remifentanil) and in Group PR (parecoxib + 
remifentanil) compared to Group C, * P = 0.001 and * P = 0.002 respectively. There was no significant difference 
between Group C and Group KR (ketorolac + remifentanil), P = 0.23. Group KR had a significant higher MAP 
compared to Group R and Group PR, * P = 0.011 and * P = 0.015 respectively (paired samples T-test). There 
were no significant differences in heart rate (HR) between the groups during the whole study-periode. The data 
are expressed as mean ± SEM. 
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Fig. 3. After keeping the current constant, the pain ratings decreased significantly, reaching 5.1 ± 0.07 (mean ± 
SEM) at 30 minutes. No significant differences between the four groups. During infusion, VRS (verbal rating 
score) decreased significantly between the three groups receiving remifentanil compared to control, P < 0.001. 
No significant differences in VRS between the three groups receiving remifentanil. After cessation of the 
infusion, VRS increased and reached control values. In Group KR (ketorolac + remifentanil) VRS exceeded 
control values and became significantly higher during the rest of the time with electrical stimulus, P = 0.036. 
The data are expressed as area under the curve (AUC) ± SEM. 
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Fig. 4. The data were transformed to areas under the curve (AUC) for each period: infusion-periode (30-60 
minutes), the post-infusion periode with electrical stimulus (60-150 minutes) and the post-infusion periode 
without electrical stimulus (150-210 minutes). Non-parametric tests with Wilcoxon were performed because the 
percentage changes were not normal distributed. The AUC in the 30-60 minutes periode was significantly less in 
Group R compared to Group C (P = 0.025), and Group PR and Group KR compared to Group C, P < 0.001. No 
significant differences between the groups receiving remifentanil. The areas of pinprick hyperalgesia exceeded 
control values in Group R in the 60-150 minutes period, P = 0.039. Pretreatment with parecoxib prevented 
postinfusion remifentanil-hyperalgesia ( P = 0.044, compared to Group R). Pretreatment with ketorolac did not 
prevent postinfusion hyperalgesia ( P = 0.53, compared to Group R). After the electrical stimulation was 
switched off, (the 150-210 minutes periode) there were no significant differences between the four groups. 
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Fig. 5A. The first cold pressor test (CPT) was similar within all participants in all of the four sessions. In Group 
C (control) there were no significant differences between CPT no. 1, 2 or 3.  
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Fig. 5B. The CPT at the end of the infusion demonstrated significantly lower VRS in all three groups receiving 
remifentanil compared to control, P < 0.001. No significant difference between the three groups receiving 
remifentanil.  
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Fig. 5C. The CPT 1 h after cessation of infusion demonstrated significantly higher VRS in Group R 
(remifentanil) compared to Group C (control), P = 0.017. Pretreatment with ketorolac (Group KR) demonstrated 
significantly lower VRS compared to Group R, P = 0.046. There were no significant differences between Group 
C, Group PR (parecoxib + remifentanil) and Group KR. The data are expressed as area under the curve (AUC) ± 
SEM.  
 
 
